A bipartisan group of 92 members of Congress yesterday urged the Food and Drug Administration to prioritize the release of an interagency task force report on the root causes of drug shortages and recommendations to address them, noting that the number of new drug shortages rose 27% last year. “Given the detrimental impact drug shortages can have on patient care, we write to urge the FDA to prioritize the release of the Drug Shortages Task Force report,” the group said in a letter to Acting FDA Commissioner Ned Sharpless, M.D., spearheaded by Reps. Eliot Engel, D-N.Y., and Brett Guthrie, R-Ky., and supported by the AHA. Former FDA Commissioner Scott Gottlieb, M.D., convened the task force last year to receive stakeholder input on the underlying systemic causes of drug shortages and recommendations to mitigate them.
 

Related News Articles

Headline
The AHA and six other organizations today submitted comments to the Drug Enforcement Administration on its proposed rule regarding controlled substances quotas.
Headline
Hospitals spend close to $360 million each year to manage drug shortages, according to a study released this week by Vizient Inc.
Headline
The House Judiciary Committee yesterday approved by voice vote the Creating and Restoring Equal Access to Equivalent Samples Act (H.R. 965).
Headline
Civica Rx, the not-for-profit generic drug company, officially opened its headquarters last week in Lehi, Utah.
Headline
The Food and Drug Administration Friday released draft guidance on how drug developers can apply for the agency’s Competitive Generic Therapies designation.
Headline
The AHA today submitted to the Food and Drug Administration legislative, regulatory and best practice recommendations to address new and chronic prescription…